Vamsi K Bollu, PhD, MBA

Research Reports

Length of Stay and Costs of COPD: Analysis of Hospitalized Patients Treated With Arformoterol or Nebulized Short-Acting Beta2-Agonists

04/11/2017

Krithika Rajagopalan, PhD

Scott B Robinson, PhD

Frank R Ernst, PharmD, MS

Tina Hunter, PhD

Bernadette H Johnson, MBA

Vamsi K Bollu, PhD, MBA

Abstract: Hospitalization costs are substantial in chronic obstructive pulmonary disease (COPD). Little is known regarding the effect of long-acting beta2-agonists (LABAs) vs short-acting beta2-agonists (SABAs) on...

...

04/11/2017

Journal of Clinical Pathways

Research Reports

Health Care Use and Costs Among Medicare Patients With Chronic Obstructive Pulmonary Disease Treated With Short-Acting Beta Agonists or Long-Acting Beta Agonists

04/11/2016

Flavia Ejzykowicz, PhD

Vamsi K Bollu, PhD, MBA

Krithika Rajagopalan, PhD

Joel W Hay, PhD

Abstract: Chronic obstructive pulmonary disease (COPD) has a high prevalence among older adults and is the third leading cause of mortality in the United States. COPD exacerbations can require hospitalizations,...

...

04/11/2016

Journal of Clinical Pathways